Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Non-Hodgkin's Lymphoma
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Non-Hodgkin's Lymphoma
    Non-Invasive Diagnostic Tool Can Differentiate Among Small Round Blue Tumours: Presented at AAP - (DGDispatch)
    CD4 Cell Count Key to Predicting Risk of Cancers in Patients With HIV - (DGNews)
    FDA Approves Pralatrexate Injection for Relapsed, Refractory Peripheral T-Cell Lymphoma - (DGNews)
    Cytarabine Plus High-Dose Methotrexate Improves Remission Rates in Primary CNS Lymphoma - (DGNews)
    FDA Approves Ibritumomab Tiuxetanton as First-Line Therapy for Non-Hodgkin's Lymphoma - (DGNews)

    News archive

     Recent webcasts/CME - Non-Hodgkin's Lymphoma
    • Exploring New Trends in MDS & AML: From Clinical Data in Poor-Prognosis Patients to Mechanisms of Novel Agents
    • Interpreting New Findings on Epigenetic Changes in MDS and AML-What Impact Will They Have on Treatment?
    • Do Modified Treatment and Novel Therapies Augment Clinical Benefit in AML?
    • Crafting an Individualized Approach to MDS Therapy: New Data on Prognostic Models and Management of Higher Risk Disease
    • Advances in the Treatment of NHL: Updates from the 2009 Pan Pacific Lymphoma Conference

      Webcasts/CME archive

       Recent cases - Non-Hodgkin's Lymphoma
        A Minute Focus of Extranodal Marginal Zone B-Cell Lymphoma Arising in Hashimoto Thyroiditis Diagnosed with PCR After Laser Capture Microdissection: A Case Report
        Lymphomatoid Granulomatosis Masquerading as Interstitial Pneumonia in a 66-Year-Old Man: A Case Report and Review of Literature
        Non-Hodgkin's Lymphoma Accompanied by Pulmonary Involvement with Diffuse Ground-Glass Opacity on Chest CT: A Report of 2 Cases
        Mantle Cell Lymphoma of the Gastrointestinal Tract Presenting with Multiple Intususceptions - A Case Report and Review of Literature
        Primary Non-Hodgkin's Lymphoma of the Infratemporal Fossa: A Rare Case Report

        Cases archive
          




        my personal edition > non-hodgkin's lymphoma > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        One Third of Patients With Mantle Cell Lymphoma Respond to Bortezomib Treatment: Presented at ASCO

        By Ed Susman

        ATLANTA, G.A. -- June 6, 2006 -- About 33% of patients with difficult-to-treat mantle cell lymphoma respond to therapy with the proteasome inhibitor bortezomib (Velcade), researchers reported here at the American Society of Clinical Oncology 2006 Annual Meeting (ASCO).

        In the single-agent phase 2 trial, 8% of patients treated with bortezomib achieved a complete response that maintained for an average of about 13.5 months.

        "These results may offer new hope for the management of mantle cell, which represents the most challenging subtype of lymphoma," said Andre Goy, MD, chief of the division of lymphoma, The Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey.

        Mantle cell lymphoma is an aggressive, rapidly progressive subtype of non-Hodgkin's lymphoma that is not curable with standard therapy. Because there is no generally accepted treatment approach and options are limited, there is a growing need for new therapies, Dr. Goy said in an oral presentation on June 4th.

        Dr. Goy and colleagues treated 155 patients diagnosed with relapsed or refractory mantle cell lymphoma with bortezomib 1.3 mg/m2 twice per week every 21 days for up to 1 year. Patients who achieve a response received a minimum of 8 cycles. All patients received at least 4 cycles of treatment.

        Results show a median duration of response of 9.2 months; median time to progression was 6.2 months; median treatment-free interval was 13.8 months, achieved in patients who had a complete response.

        The most common nonhematologic adverse event was fatigue, Dr. Goy said. About 14% of these cases reached grade 3 level -- a level of fatigue that interferes with activities of daily living. About 5% of patients suffered grade 3 diarrhea, about 4% experienced grade 3 abdominal pain, and about 3% had grade 3 nausea/vomiting. About 7% of patients experienced grade 3 peripheral neuropathies.

        "These results reinforce the safety and efficacy observed in multiple other phase 2 studies of bortezomib, which showed its potential to become a new standard of care for relapsed patients."


        [Presentation title: Bortezomib in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Results of the PINNACLE Study. Abstract 7512]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send